Figure 6. Inhibition of HIV-1 transfer and activity in the human VEC organotypic model tissues transduced with AAV-6 expressing b12 minibodies.

AAV-6-b12 minibodies or AAV-6-11A minibodies (control) at 5×10¹⁰ particles was applied to the upper layers of the VEC tissues for 24 h for transduction. Four days after the transduction, HIV-1_bal (50 ng) was applied to the upper layers of the tissues, and medium from the basal chambers were collected at various timepoints and tested for inhibition of viral transfer (A) and infectivity (B) as in Fig. 5.